SCHEMBL14964682

SCHEMBL14964682

OCCCc1ncccc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.64
ALDH1A1 P00352 1/20 0.64
KDM4E B2RXH2 6/20 0.58
HSD17B10 Q99714 1/20 0.53
CXCR4 P61073 2/20 0.47
CYP2C19 P33261 1/20 0.46
HIF1A Q16665 1/20 0.46
CHRM1 P11229 2/20 0.39
TSHR P16473 2/20 0.39
MMP2 P08253 1/20 0.39
COMT P21964 1/20 0.39
ADRA1A P35348 1/20 0.39
METAP2 P50579 1/20 0.39
METAP1 P53582 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
KDM1A O60341 1/20 0.39
LMNA P02545 2/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31308700 0.88 ALDH1A1 (0.69) L3MBTL1ALDH1A1KDM4EHSD17B10CXCR4
SCHEMBL2386030 0.82 L3MBTL1 (0.57) L3MBTL1ALDH1A1KDM4EHSD17B10CYP2C19
SCHEMBL27863560 0.82 L3MBTL1 (0.57) L3MBTL1ALDH1A1KDM4EHSD17B10CXCR4
SCHEMBL1081794 0.81 L3MBTL1 (0.55) L3MBTL1ALDH1A1KDM4EHSD17B10CYP2C19
SCHEMBL11604545 0.81 ALDH1A1 (0.55) L3MBTL1ALDH1A1KDM4EHSD17B10CXCR4
SCHEMBL28202954 0.79 L3MBTL1 (0.53) L3MBTL1ALDH1A1KDM4EHSD17B10HIF1A
SCHEMBL1179397 0.79
SCHEMBL30463155 0.79
SCHEMBL20099885 0.78 CXCR4 (0.49) L3MBTL1ALDH1A1KDM4EHSD17B10CXCR4
SCHEMBL11090688 0.78 ALDH1A1 (0.52) L3MBTL1ALDH1A1KDM4EHSD17B10CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3315492-B1 PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2020-09-16 EP disclosed
EP-2780342-B1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO LTD (CN) 2016-06-01 EP disclosed
US-9181277-B2 Aminoquinazoline derivatives and their salts and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-11-10 US disclosed
US-9181277-B2 Aminoquinazoline derivatives and their salts and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-11-10 US disclosed
US-9181277-B2 Aminoquinazoline derivatives and their salts and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-11-10 US disclosed
CN-103102344-B Amino quinazoline derivative and salt thereof and using method SUNSHINE LAKE PHARMA CO.,LTD. (CN) 2015-10-14 CN disclosed
EP-2780342-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE Sunshine Lake Pharma Co., Ltd. (CN) 2014-09-24 EP disclosed
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-08-14 US disclosed
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-08-14 US disclosed
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-08-14 US disclosed
WO-2013071697-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2013-05-23 WO disclosed
WO-2013071697-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2013-05-23 WO disclosed
CN-103102344-A Aminoquinazoline derivative, salts thereof and application method GUANGDONG HEC PHARMACEUTICAL 2013-05-15 CN disclosed
CN-102675236-A Synthesis method of ethyl formate 5-chloro-3-(methylthio)-1,2,4-triazinyl-6-carboxylic acid CGENE TECH SUZHOU CHINA CO LTD 2012-09-19 CN disclosed
CN-102516253-A Method for synthesizing 3,4-dihydro-2H-pyrano[3,2-b]pyridine CGENE TECH SUZHOU CHINA CO LTD 2012-06-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE ABL1, PRKDC, JAK2 L3MBTL1 4063/4885ALDH1A1 4099/4885KDM4E 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.